Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes.


Journal

Gynecologic and obstetric investigation
ISSN: 1423-002X
Titre abrégé: Gynecol Obstet Invest
Pays: Switzerland
ID NLM: 7900587

Informations de publication

Date de publication:
2019
Historique:
received: 10 04 2018
accepted: 20 08 2018
pubmed: 3 1 2019
medline: 6 8 2019
entrez: 3 1 2019
Statut: ppublish

Résumé

To compare baseline risk factors for type 1 vs. 2 endometrial cancers and analyze these risk factors for association with overall survival and time to recurrence. Retrospective review of 816 consecutive endometrial cancer cases was conducted with diagnosis from January 2005 to December 2010 and clinical course until 2016. Risk factors, treatment, recurrence, and death were compared using 2 sample t tests, χ2 test and Cox Regression models. There were 550 cases of type 1 and 266 cases of type 2 cancer. Patients with type 2 disease were older (p < 0.001), less obese (p = 0.03), non-white (p < 0.001), and menopausal (p = 0.02). There was no difference in use of oral contraceptives, hormone replacement therapy (HRT), smoking, or major cardiovascular disease. Cox Regression models showed that type 2 disease (p < 0.001) and advanced stage (p = 0.001) were associated with recurrence. Consistent with previous literature, our analysis found that type 2 cancer is more common in non-white, older, and less obese patients and associated with higher mortality and recurrence. However, inconsistent with previous literature, we found no association between type 2 cancer and diabetes mellitus or use of HRT. These factors should be considered when approaching patients with endometrial cancer.

Identifiants

pubmed: 30602164
pii: 000493132
doi: 10.1159/000493132
doi:

Substances chimiques

Contraceptives, Oral 0

Types de publication

Comparative Study Journal Article

Langues

eng

Pagination

290-297

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Jacqueline Feinberg (J)

Yale University School of Medicine, New Haven, Connecticut, USA, jackie.feinberg@yale.edu.

Benjamin Albright (B)

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Jonathan Black (J)

Yale University School of Medicine, New Haven, Connecticut, USA.

Lingeng Lu (L)

Yale University School of Medicine, New Haven, Connecticut, USA.

Rachel Passarelli (R)

Yale University School of Medicine, New Haven, Connecticut, USA.

Stefan Gysler (S)

Yale University School of Medicine, New Haven, Connecticut, USA.

Margaret Whicker (M)

Yale University School of Medicine, New Haven, Connecticut, USA.

Gary Altwerger (G)

Yale University School of Medicine, New Haven, Connecticut, USA.

Gulden Menderes (G)

Yale University School of Medicine, New Haven, Connecticut, USA.

Pei Hui (P)

Yale University School of Medicine, New Haven, Connecticut, USA.

Alessandro D Santin (AD)

Yale University School of Medicine, New Haven, Connecticut, USA.

Masoud Azodi (M)

Yale University School of Medicine, New Haven, Connecticut, USA.

Dan-Arin Silasi (DA)

Yale University School of Medicine, New Haven, Connecticut, USA.

Elena S Ratner (ES)

Yale University School of Medicine, New Haven, Connecticut, USA.

Babak Litkouhi (B)

Yale University School of Medicine, New Haven, Connecticut, USA.

Peter E Schwartz (PE)

Yale University School of Medicine, New Haven, Connecticut, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH